Home / Stocks / Nureca Limited
NURECA Updated about 8 hours ago

Nureca Limited Share Price

NSE closing price and which mutual funds hold this stock

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 19 Nov 2026

₹298.65

Change

-3.7 (-1.22%)

Open

₹300.0

Prev. Close

₹302.35

Day High

₹301.9

Day Low

₹295.1

Volume Analysis

Traded

1,352

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (3)

  • •Low return on equity (1.12%)
  • •Below-average fundamentals quality score (40/100)
  • •Low operating margin (3.5%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹308.8 ₹305.35 ₹302.0 ₹298.55 ₹295.2 ₹291.75 ₹288.4
Fibonacci ₹305.35 ₹302.75 ₹301.15 ₹298.55 ₹295.95 ₹294.35 ₹291.75
Camarilla ₹300.52 ₹299.9 ₹299.27 ₹298.55 ₹298.03 ₹297.4 ₹296.78

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-3.91%

1 Week

-1.32%

1 Month

-9.2%

3 Months

-2.62%

6 Months

+9.72%

1 Year

+15.04%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹98.3

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

2.26%

Net margin 2.87% × asset turnover 0.64x × equity multiplier 1.23x

Company Overview

Sector

Healthcare

Market Cap

₹293 Cr

P/E (TTM)

61.4

ROE

1.12%

Book Value

₹197.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Nureca Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 40/100. The strongest factor is Financial Strength (100/100), while Liquidity (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (1.12%); below-average fundamentals quality score (40/100).

TopFund Score — Fundamentals Quality

40/100 — Weak

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

16

Valuation

25

Cash Flow

10

Corporate Governance

66

Momentum

61

Institutional Ownership

30

Business Quality

29

Risk & Volatility

49

Liquidity

0

From Screener.in

  • +Company is almost debt free.
  • +Company is expected to give good quarter
  • +Promoter holding has increased by 2.59% over last quarter.
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of -7.19% over past five years.
  • −Company has a low return on equity of -0.55% over last 3 years.
  • −Earnings include an other income of Rs.6.38 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Nureca disclosed Ms. Smita Goyal, promoter group member, purchased company shares on November 12, 2026.

CRISIL assigns Nureca bank facilities ratings: Rs80 crore rated BB+/Stable and A4+.

Q2 FY27 revenue rose 55% to ₹58.53 crore; PAT increased 12% to ₹4.05 crore.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 31 22 17 20 31 26 32 34 38 40 35 40 59
Expenses + 30 27 21 23 34 30 31 35 34 36 41 37 53
Operating Profit 1 -4 -4 -2 -2 -4 1 -1 3 3 -6 3 5
OPM % 4.4% -19.0% -26.1% -11.64% -7.53% -15.15% 3.78% -1.64% 8.66% 8.2% -16.32% 8.48% 8.94%
Other Income + 3 6 -1 6 3 1 2 3 2 2 1 2 1
Interest 0 0 0 0 0 0 1 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 0 1 1
Profit before tax 4 1 -6 3 0 -3 2 1 5 5 -6 4 6
Tax % 25.83% 82.11% -35.86% 36.64% 585.71% -13.85% -20.0% 34.15% 21.13% 19.96% 10.71% 30.93% 26.5%
Net Profit + 3 0 -4 2 0 -3 2 1 4 4 -6 3 4
EPS in Rs 3 0 -4 2 0 -3 2 1 4 4 -6 3 4
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -15 -20 -20 -5 -1 18 87 69 21 50 12 18 55

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 62 99 213 256 111 92 110 147 174
Expenses + 53 90 152 200 126 102 117 147 168
Operating Profit 9 10 62 56 -15 -10 -8 0 6
OPM % 15.0% 10.0% 29.0% 22.0% -13.0% -11.0% -7.0% 0.1% 3.5%
Other Income + 0 0 3 8 7 11 12 8 6
Interest 0 1 2 1 0 0 1 1 1
Depreciation 0 0 0 1 2 2 2 2 2
Profit before tax 9 9 62 61 -11 -3 1 5 9
Tax % 30.0% 26.0% 26.0% 26.0% -23.0% -30.0% 37.0% 58.0% —
Net Profit + 6 6 46 45 -8 -2 1 2 5
EPS in Rs 623 640 46 45 -8 -2 1 2 5
Dividend Payout % 0.0% 0.0% 4.0% 7.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 61 115 20 -56 -17 19 34 34

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 8 15 153 193 185 183 184 171 178
Borrowings + 0 10 4 4 3 3 5 2 7
Other Liabilities + 15 9 19 12 8 10 11 13 37
Total Liabilities 24 34 186 219 207 205 210 196 231
Fixed Assets + 1 1 4 10 9 7 9 14 18
CWIP 0 0 0 0 0 0 0 0 5
Investments 0 0 0 33 59 94 1 1 3
Other Assets + 23 33 182 175 139 104 200 182 205
Total Assets 24 34 186 219 207 205 210 196 231
Equity Capital 0 0 10 10 10 10 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 0 -8 35 1 10 -3 -19 3
Cash from Investing Activity + 0 0 -110 -3 -16 18 8 14
Cash from Financing Activity + 0 8 92 -7 -2 -1 0 -20
Net Cash Flow 0 0 17 -9 -8 14 -11 -2
Free Cash Flow 0 -8 34 -5 10 -4 -23 -3
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 4 -82 81 35 -96 39 234 1,464

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 63.24% → 70.68%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 36.69% 36.69% 36.69% 35.53% 35.54% 34.59% 35.56% 34.92% 34.91% 31.39% 31.57% 28.85%
Promoters 63.24% 63.24% 63.24% 63.78% 64.06% 64.3% 64.33% 64.97% 64.97% 68.09% 68.09% 70.68%
FII 0.07% 0.07% 0.07% 0.69% 0.36% 1.07% 0.07% 0.07% 0.08% 0.28% 0.11% 0.22%
DII 0.0% 0.0% 0.0% 0.0% 0.04% 0.04% 0.04% 0.04% 0.04% 0.24% 0.24% 0.24%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Nureca Limited (this stock) 293 61.4 1.56 1.12%
Ambalal Sarabhai Ent L 304 19.6 1.86 12.4%
Lyka Labs Ltd. 328 — 3.39 -10.2%
Qms Medical Allied S Ltd 336 31.3 3.23 10.4%
Brooks Lab Limited 203 58.7 1.08 22.0%
Bilcare Ltd. 202 5.55 1.13 1.39%
Nectar Lifesciences Ltd. 193 — 0.34 -31.3%

Which Mutual Funds Hold Nureca Limited?

Frequently Asked Questions about Nureca Limited

Community Sentiment

What are other investors saying about Nureca Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.